Complete local tumor regression with antibody to fibrin Fragment E.
Rabbit antibody to fibrin fragment E (FFE) was used in an immunotherapy model for the treatment of the line-10 ascites variant of a diethylnitrosamine-induced hepatoma in strain 2 guinea pigs. When 0.75 or 1.0 mg of an IgG preparation containing anti-FFE antibody was injected s.c. 6 and 16 days after the injection of a uniformly lethal dose of line-10 tumor cells, complete regression of the i.d. growing tumor was observed in all 18 strain 2 guinea pigs treated. Thus, this therapy appears to be more effective than any BCG or other immunotherapeutic regimen thus far reported for this tumor. No significant anti-tumor effect was noted when normal rabbit IgG or smaller doses (0.25 or 0.50 mg) of the anti-FFE IgG preparation were used. The injection sites exhibited an inflammatory response for 7 to 10 days characterized by erythema and hemorrhage. Since all animals were treated after the metastatic progression of the tumor is known to frequently occur, the long-term tumor-free survival of these animals as well as their  resistance to subsequent tumor challenge indicate that the anti-FFE antibody therapy led to systemic tumor immunity.
D000818:Animals; D000906:Antibodies / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000628:therapy*; D003378:Counterimmunoelectrophoresis; D005337:Fibrin / Q000276:immunology* / Q000302:isolation & purification; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007106:Immune Sera / Q000302:isolation & purification; D007115:Immunization Schedule; D005779:Immunodiffusion; D007167:Immunotherapy; D007271:Injections, Intradermal; D008113:Liver Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology; D011817:Rabbits; D012867:Skin / Q000473:pathology
D000906:Antibodies; D007106:Immune Sera; D005337:Fibrin